CHRISTOPHER BELL: Open Payments
NPI 1225190382 · TUPELO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$119,731 in 214 payments from 14 companies in 2025. Trend: 2023 $78,515 · 2024 $103,090 · 2025 $119,731
Speaker / faculty: $81,916Travel & lodging: $19,248Consulting: $14,077Food & beverage: $4,490
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 57 | $45,673 |
| Alnylam Pharmaceuticals Inc. | 64 | $36,474 |
| BridgeBio Pharma, Inc. | 38 | $12,294 |
| E.R. Squibb & Sons, L.L.C. | 22 | $12,249 |
| Novo Nordisk Inc | 4 | $7,166 |
| CVRx, Inc. | 7 | $4,233 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $994 |
| Abbott Laboratories | 3 | $286 |
| Boston Scientific Corporation | 4 | $203 |
| Lexicon Pharmaceuticals, Inc. | 1 | $55 |
Products named: WAINUA, AMVUTTRA, Attruby, CAMZYOS, Ozempic, Barostim Neo System, FREESTYLE LIBRE PRO, General - Therapies.
Industry payments across MS — which companies pay providers there.
